AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
Cristina Arriens(Oklahoma Medical Research Foundation), Coburn Hobar(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Eric F. Morand(Novartis (Switzerland)), A. Stevens(Bristol-Myers Squibb (United States)), Kathleen Connors(Bristol-Myers Squibb (United States)), T. Wegman(Bristol-Myers Squibb (United States)), Richard Furie(Hofstra University), Anca Askanase(Columbia University Irving Medical Center), Ronald van Vollenhoven(Amsterdam University Medical Centers), M. K. Davey(Bristol-Myers Squibb (United States)), V. Shah(Bristol-Myers Squibb (United States))
Cited by 2
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840